Cargando…

Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden

INTRODUCTION: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) can reveal the metabolic activity of malignant tumors. Recent advances gained from molecular studies suggest that tumor biology can be a good predictor of prognosis in breast cancer. We compared the ability of maximum stan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Sung Gwe, Park, Jong Tae, Lee, Hak Min, Lee, Hak Woo, Jeon, Tae Joo, Han, Kyunghwa, Lee, Seung Ah, Dong, Seung Myung, Ryu, Young Hoon, Son, Eun Ju, Jeong, Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308858/
https://www.ncbi.nlm.nih.gov/pubmed/25551703
http://dx.doi.org/10.1186/s13058-014-0502-y
_version_ 1782354598527238144
author Ahn, Sung Gwe
Park, Jong Tae
Lee, Hak Min
Lee, Hak Woo
Jeon, Tae Joo
Han, Kyunghwa
Lee, Seung Ah
Dong, Seung Myung
Ryu, Young Hoon
Son, Eun Ju
Jeong, Joon
author_facet Ahn, Sung Gwe
Park, Jong Tae
Lee, Hak Min
Lee, Hak Woo
Jeon, Tae Joo
Han, Kyunghwa
Lee, Seung Ah
Dong, Seung Myung
Ryu, Young Hoon
Son, Eun Ju
Jeong, Joon
author_sort Ahn, Sung Gwe
collection PubMed
description INTRODUCTION: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) can reveal the metabolic activity of malignant tumors. Recent advances gained from molecular studies suggest that tumor biology can be a good predictor of prognosis in breast cancer. We compared the ability of maximum standardized uptake values (SUV(max)) derived by FDG-PET with tumor burden in predicting tumor recurrence for patients with breast cancer. METHODS: 496 patients with breast cancer who underwent preoperative FDG-PET between April 2004 and May 2009 were retrospectively identified. SUV(max) was obtained by FDG-PET, and the cutoff point was defined using a time-dependent receiver operating characteristic curve for recurrence-free survival (RFS). The primary endpoint was RFS. RESULTS: In multivariate analysis for RFS, SUV(max) carried independent prognostic significance (hazard ratio, 2.39; 95% confidence interval, 1.20 to 4.76; P = 0.012). When the patients were classified into four groups according to the combined factors of tumor size (≤2 cm versus >2 cm) and SUV(max) (<4 versus ≥4), RFS differed significantly (P < 0.001). Similarly, SUV(max) had prognostic value in combination with nodal status (negative versus positive) or stage (I versus II and III) (P < 0.001 and P = 0.001, respectively). In hormone receptor–positive disease, SUV(max) remained a significant prognostic factor for RFS based on multivariate analysis. CONCLUSIONS: Our results highlight the prognostic value of FDG-PET in prediction of tumor relapse for patients with breast cancer. Particularly in patients with hormone receptor–positive disease, the tumor metabolic information provided by FDG-PET is more significantly correlated with prognosis than tumor burden. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-014-0502-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4308858
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43088582015-01-29 Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden Ahn, Sung Gwe Park, Jong Tae Lee, Hak Min Lee, Hak Woo Jeon, Tae Joo Han, Kyunghwa Lee, Seung Ah Dong, Seung Myung Ryu, Young Hoon Son, Eun Ju Jeong, Joon Breast Cancer Res Research Article INTRODUCTION: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) can reveal the metabolic activity of malignant tumors. Recent advances gained from molecular studies suggest that tumor biology can be a good predictor of prognosis in breast cancer. We compared the ability of maximum standardized uptake values (SUV(max)) derived by FDG-PET with tumor burden in predicting tumor recurrence for patients with breast cancer. METHODS: 496 patients with breast cancer who underwent preoperative FDG-PET between April 2004 and May 2009 were retrospectively identified. SUV(max) was obtained by FDG-PET, and the cutoff point was defined using a time-dependent receiver operating characteristic curve for recurrence-free survival (RFS). The primary endpoint was RFS. RESULTS: In multivariate analysis for RFS, SUV(max) carried independent prognostic significance (hazard ratio, 2.39; 95% confidence interval, 1.20 to 4.76; P = 0.012). When the patients were classified into four groups according to the combined factors of tumor size (≤2 cm versus >2 cm) and SUV(max) (<4 versus ≥4), RFS differed significantly (P < 0.001). Similarly, SUV(max) had prognostic value in combination with nodal status (negative versus positive) or stage (I versus II and III) (P < 0.001 and P = 0.001, respectively). In hormone receptor–positive disease, SUV(max) remained a significant prognostic factor for RFS based on multivariate analysis. CONCLUSIONS: Our results highlight the prognostic value of FDG-PET in prediction of tumor relapse for patients with breast cancer. Particularly in patients with hormone receptor–positive disease, the tumor metabolic information provided by FDG-PET is more significantly correlated with prognosis than tumor burden. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-014-0502-y) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-31 2014 /pmc/articles/PMC4308858/ /pubmed/25551703 http://dx.doi.org/10.1186/s13058-014-0502-y Text en © Ahn et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ahn, Sung Gwe
Park, Jong Tae
Lee, Hak Min
Lee, Hak Woo
Jeon, Tae Joo
Han, Kyunghwa
Lee, Seung Ah
Dong, Seung Myung
Ryu, Young Hoon
Son, Eun Ju
Jeong, Joon
Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
title Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
title_full Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
title_fullStr Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
title_full_unstemmed Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
title_short Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
title_sort standardized uptake value of (18)f-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308858/
https://www.ncbi.nlm.nih.gov/pubmed/25551703
http://dx.doi.org/10.1186/s13058-014-0502-y
work_keys_str_mv AT ahnsunggwe standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT parkjongtae standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT leehakmin standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT leehakwoo standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT jeontaejoo standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT hankyunghwa standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT leeseungah standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT dongseungmyung standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT ryuyounghoon standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT soneunju standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden
AT jeongjoon standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden